Journal of Clinical Endocrinology & Metabolism, Vol 75, 417-423, Copyright © 1992 by Endocrine Society

ARTICLES

A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man

LJ Fraher, AB Hodsman, K Jonas, D Saunders, CI Rose, JE Henderson, GN Hendy and D Goltzman
Department of Medicine, Lawson Research Institute, St. Joseph's Health Centre, London, Ontario, Canada.

PTH-related peptide (PTHrP) is one of the etiological factors associated with hypercalcemia of malignancy in humans and rodents. In both in vivo and in vitro animal systems its actions mimic those of PTH; however, its bioactivity in humans has not previously been assessed. Therefore, we compared the actions of the synthetic human (h) analogs hPTHrP-(1-34) and hPTH-(1-34) when given by iv infusion to 15 healthy subjects, aged 25 +/- 3 yr. Three 12-h test infusions were given to each subject in the order: hPTH-(1-34) at a dose of 8 pmol/kg.h, an equimolar dose (8 pmol/kg.h) of PTHrP-(1-34) (low dose), and a 10-fold higher dose (80 pmol/kg.h) of hPTHrP-(1-34) (high dose). PTH infusion resulted in significant increases from basal values in serum total ionized calcium, urinary phosphate and cAMP, and serum 1,25- dihydroxyvitamin D3 [1,25-(OH)2d3]. No significant increases from basal values in any of these variables were observed during low dose PTHrP infusion. However, a 10-fold higher dose of PTHrP significantly increased serum calcium from 2.36 +/- 0.07 to 2.63 +/- 0.16 mmol/L (P less than 0.003), ionized calcium from 1.22 +/- 0.03 to 1.39 +/- 0.09 mmol/L (P less than 0.003), urinary phosphate from 0.21 +/- 0.19 to 0.31 +/- 0.16 mmol/L glomerular filtrate (P less than 0.05), urinary cAMP from 37 +/- 18 to 53 +/- 28 nmol/L glomerular filtrate (P less than 0.01), and serum 1,25-(OH)2D3 from 29.8 +/- 12.1 to 46.0 +/- 20.3 pmol/L (P less than 0.01). For each variable these changes were statistically equivalent to the increases observed during PTH infusion. The molar concentrations of circulating immunoreactive PTH-(1-34) and PTHrP-(1-34) (at the higher dose) achieved during infusion were at a ratio of 1:3. These results suggest that the in vivo actions of synthetic hPTHrP-(1-34) are comparable to those of hPTH-(1-34), but its biological activity after infusion may be less than that of hPTH-(1- 34). Moreover, the increased concentrations of serum 1,25-(OH)2D3 observed with administration of hPTHrP-(1-34) are unlike the changes seen in hypercalcemia of malignancy in which levels of this vitamin D metabolite are frequently depressed.

This article has been cited by other articles:

				G. S Bevelander, E. S L C Pinto, A. V M Canario, T. Spanings, and G. Flik CYP27A1 expression in gilthead sea bream (Sparus auratus, L.): effects of calcitriol and parathyroid hormone-related protein J. Endocrinol., March 1, 2008; 196(3): 625 - 635. [Abstract] [Full Text] [PDF]

				M. J. Horwitz, M. B. Tedesco, S. M. Sereika, B. W. Hollis, A. Garcia-Ocana, and A. F. Stewart Direct Comparison of Sustained Infusion of Human Parathyroid Hormone-Related Protein-(1-36) [hPTHrP-(1-36)] Versus hPTH-(1-34) on Serum Calcium, Plasma 1,25-Dihydroxyvitamin D Concentrations, and Fractional Calcium Excretion in Healthy Human Volunteers J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1603 - 1609. [Abstract] [Full Text] [PDF]

				M. A. Syed, M. J. Horwitz, M. B. Tedesco, A. Garcia-Ocaña, S. R. Wisniewski, and A. F. Stewart Parathyroid Hormone-Related Protein-(1-36) Stimulates Renal Tubular Calcium Reabsorption in Normal Human Volunteers: Implications for the Pathogenesis of Humoral Hypercalcemia of Malignancy J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1525 - 1531. [Abstract] [Full Text]

				M. Mannstadt, H. Juppner, and T. J. Gardella Receptors for PTH and PTHrP: their biological importance and functional properties Am J Physiol Renal Physiol, November 1, 1999; 277(5): F665 - F675. [Abstract] [Full Text] [PDF]

				L. J. Fraher, R. Avram, P. H. Watson, G. N. Hendy, J. E. Henderson, K. L. Chong, D. Goltzman, P. Morley, G. E. Willick, J. F. Whitfield, et al. Comparison of the Biochemical Responses to Human Parathyroid Hormone-(1-31)NH2 and hPTH-(1-34) in Healthy Humans J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2739 - 2743. [Abstract] [Full Text]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				M. Wolzt, L. Schmetterer, G. Dorner, G. Zelger, J. Entlicher, S. Kapiotis, and H.-G. Eichler Hemodynamic Effects of Parathyroid Hormone-Related Peptide-(1-34) in Humans J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2548 - 2551. [Abstract] [Full Text] [PDF]

				J. G. Henry, M. Mitnick, P. R. Dann, and A. F. Stewart Parathyroid Hormone-Related Protein-(1-36) Is Biologically Active When Administered Subcutaneously to Humans J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 900 - 906. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, L. J. Fraher, P. H. Watson, T. Ostbye, L. W. Stitt, J. D. Adachi, D. H. Taves, and D. Drost A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 620 - 628. [Abstract] [Full Text] [PDF]

				E. B. Mawer, J. Walls, A. Howell, M. Davies, W. A. Ratcliffe, and N. J. Bundred Serum 1,25-Dihydroxyvitamin D May Be Related Inversely to Disease Activity in Breast Cancer Patients with Bone Metastases J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 118 - 122. [Abstract] [Full Text] [PDF]

				W. Huang, U.-i. Chung, H. M. Kronenberg, and B. de Crombrugghe The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones PNAS, January 2, 2001; 98(1): 160 - 165. [Abstract] [Full Text] [PDF]